Under one in 10 individuals that would benefit from weight-loss injections like Wegovy can access them, states the World Health Organization as it issues its first recommendations on the drugs.
With over a billion individuals worldwide currently living with obesity, it is advocating for broader and more equitable availability to GLP-1 medication.
According to projections, in excess of 2,000,000,000 could be living with obesity by 2030 without intervention.
"The latest guidelines affirms that obesity is a long-term condition that can be managed with holistic and ongoing treatment," said the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant hurdles to widespread availability to the jabs that can assist patients in reducing substantial body mass, notes the organization.
Skinny Jab Supply Crisis
Despite the current most optimistic outlook, the supply of such drugs might only reach around 100 million people – fewer than 10% of eligible patients, according to the health organization.
The recommendation encourages countries and companies to increase access, through approaches including patent sharing.
A patent on semaglutide – the primary component of a leading brand – is due to expire in several countries in 2026.
How Obesity Injections Function
The injections imitate a biological compound to reduce digestion speed, suppress the appetite and boost the sense of being full so individuals reduce food intake.
People usually see weight reduction within a few weeks of beginning the once-weekly jabs.
Research suggests users may regain a significant portion within a year of stopping the drug, when their normal food cravings come back.
To be above a healthy weight elevates your risk for contracting health problems, like type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns individuals in countries worldwide and was linked to millions of fatalities worldwide in 2024, according to the WHO.
